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   Objective: 10-17% of women with LSIL cytology truly have CIN 2+ disease at 
colposcopically directed biopsy and 20% of the CIN 2+ lesions derive from women with 
LSIL cytology. No molecular marker has yet been able to triage LSIL cytology 
effectively. If possible, the triage would spare women the referral to colposcopy.  
Irreversible chromosomal damage occurs during oncogenesis. Increasing cervical 
dysplastic severity occurs with increasing amplification of the 3q26 chromosomal region. 
The purpose of this study is to evaluate the test characteristics of 3q26 amplification in 
women whose routine cytology is reported as LSIL with emphasis on the negative 
predictive value for reassurance. Methods:  We conducted a retrospective study using 
the available SurePath™ liquid cytology LSIL archival samples from women 17-59 
years old which were linked to colposcopically directed biopsy samples taken on 
average 36 days after cytology sampling (3-90 day range). Nuclei from the LSIL 
samples were hybridized with a single-copy probe for the chromosome 3q26 region and 
a control probe for the centromeric alpha repeat sequence of chromosome 7, using 
standard FISH methods. Amplification was defined as five or more signals present in at 
least 2 cells.  Results: Of the 68 paired cytology/biopsy samples, 3q26 amplification 
occurred in 40% of the women with CIN 2+ disease (sensitivity 95% CI: 12, 74). There 
was no amplification in 91% of women with less than CIN 2 disease (specificity 95% CI: 
81, 97); and the negative predictive value was 90% (79, 96).  
Conclusions:  The lack of 3q26 amplification in women with screening cytology LSIL 
results offers reassurance that CIN 2+ disease has not developed. Future prospective 
studies are ongoing. 
 
